Company / Gross Margin
Edwards Lifesciences Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
78.0%
FY2025
5-year range
76.1% / 83.8%
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#6 of 96
Health Care
What the data says
Among 96 Health Care companies, Edwards Lifesciences is in the top 6% for gross margin. Gross Margin has fluctuated over the past 10 years, ranging from 73.1% in FY2016 to 83.8% in FY2022.
Based on SEC 10-K filings.
78.0% in FY2025 with a 5-year CAGR of +2.6%. Top quartile in the Health Care sector.
Improved from 76.1% to 78.0% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -5.8pp
- 5-Year Change
- +2.6pp
- 10-Year Change
- -
Sector benchmark
Top 6% in Health CareTop 6% of 96This company 78.0% Sector average 53.6%
▼
+45.6% above sector average
Key checks
Key Insights
- In FY2025, gross margin decreased 1.8% year-over-year.
- Currently 24.4pp above the Health Care sector average.
- Peak gross margin was recorded in FY2022.
- Lowest gross margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 78.0% | -1.8% |
| FY2024 | 79.5% | +4.4% |
| FY2023 | 76.1% | -9.1% |
| FY2022 | 83.8% | +10.1% |
| FY2021 | 76.1% | +1.0% |
| FY2020 | 75.4% | +1.3% |
| FY2019 | 74.4% | -0.5% |
| FY2018 | 74.8% | +0.3% |
| FY2017 | 74.5% | +2.0% |
| FY2016 | 73.1% | -2.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026